<DOC>
	<DOC>NCT00602849</DOC>
	<brief_summary>The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to ZoloftÂ® Tablets, 100 mg (Pfizer) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of Sertraline Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Sertraline</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. Treatment with any triptan within 30 days prior to or during the study. History of allergic or adverse response to sertraline or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>